LLY vs NVO

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Novo Nordisk (NVO) remains a formidable pharmaceutical giant, leading in diabetes and obesity care with its dominant GLP-1 franchise. The company is financially robust, boasts significant proprietary assets, and has a strategic vision for new therapeutic applications and AI integration. Recent FDA approvals for Wegovy HD and oral Wegovy are positive developments, enhancing its product portfolio. H...